Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma. It is available as a tablet.

Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.

Zafirlukast is marketed by AstraZeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil and China.

External links

• Accolate, Accoleit, Vanticon (manufacturer's website)
• Zafirlukast (patient information)

Leukotriene antagonists